No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
www.uniqure.comNo one on the platform currently holds 0EE0.L.
No tracked institution reports a position in 0EE0.L as of their last filing.
No one on the platform has traded 0EE0.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -40.6% | -15.6% | ||||
| Profit Margin % | -1236.0% | -824.5% | -779.7% | |||
| Free Cash Flow Margin % | -1108.2% | -572.4% | -629.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $22M | +41.2% | $-3.89 | $-11.88–$0.09 | — | 1 |
| 2027 | $131M | +489.7% | $-3.03 | $-9.25–$0.07 | — | 1 |
| 2028 | $401M | +205.0% | $-1.19 | $-3.62–$0.03 | — | 1 |
| 2029 | $633M | +57.9% | $1.05 | $-0.02–$3.19 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $-0.82 | $-1.22 | -48.4% |
| 2026-05-05 | $-0.86 | $-0.85 | +1.7% |
| 2026-03-02 | $-0.91 | $-0.57 | +37.6% |
| 2025-11-10 | $-0.90 | $-1.38 | -52.4% |
| 2025-07-29 | $-0.89 | $-0.69 | +23.1% |
| 2025-05-09 | $-1.00 | $-0.82 | +18.1% |
| 2025-02-27 | $-0.65 | $-1.50 | -129.7% |
| 2024-11-05 | $-0.99 |
| $-0.91 |
| +8.2% |
| +3.40% |
| $370M |
| — |
| 0IV3.LGeron Corporation | $1.31 | -0.91% | $874M | — |
| 0JBU.LIntellia Therapeutics, Inc. | $11.74 | +2.04% | $1.3B | — |
Source: Financial Modeling Prep · peers by sector/industry